Skip to content
Search

Latest Stories

Cimetidine, Famotidine and Nizatidine face supply disruption

The H2-antagonists including Cimetidine, Famotidine, and Nizatidine are facing supply disruption. Latest update on the supply of these products is given below…

ProductSupplierCurrent Stock PositionAnticipated Resupply dateDetail
Famotidine 20mg tabletsTilomed LaboratoriesLimited suppliesEarly December 2020Unlicensed supplies have been sourced
Teva UKOut of stockMid November 2020
Famotidine 40mg tabletsTilomed LaboratoriesIn stockN/A
Teva UKLimited suppliesEnd November 2020
Cimetidine 200mg tabletsEnnogen PharmaOut of stockJune 2021Unlicensed supplies have been sourced
MedreichOut of stockto be confirmed
Cimetidine 400mg tabletsEnnogen PharmaOut of stockJune 2021
MedreichOut of stockto be confirmed
Cimetidine 800mg tabletsEnnogen PharmaOut of stockJune 2021
MedreichOut of stockto be confirmed
Cimetidine 200mg/5ml oral solutionRosemont PharmaceuticalsIn stockn/a
Nizatidine 150mg tabletsMylanOut of stockEarly January 2021Unlicensed supplies have been sourced
MedreichOut of stockto be confirmed
RelonchemOut of stockEnd November 2020
Nizatidine 300mg tabletsMylanOut of stockEarly January 2021Unlicensed supplies of Nizatidine 150mg capsules have been sourced
MedreichOut of stockto be confirmed
RelonchemOut of stockIn stock

Alium Medical,  Mawdsley’s Unlicensed, Durbin PLC, and Target Healthcare have confirmed that they can source unlicensed Cimetidine 200mg, 400mg, and 800mg tablets. The three drug manufacturers have also assured that they can supply Famotidine tablets 20mg and 40mg


Ennogen and UL Global will be able to supply Cimetidine 200mg, 400mg and famotidine 20mg and 40mg tablets respectively to avert any severe scarcity of the medicines.

Mawdsley’s Unlicensed and Target Healthcare have confirmed that they can source unlicensed Nizatidine capsules.

There is currently no listing on dm+d for the imported product for prescribers to select using their prescribing systems so an EPS prescription for unlicensed Cimetidine tablets cannot be issued.

If a prescriber wishes to prescribe an unlicensed import, an FP10 paper prescription should be issued as ‘Cimetidine (strength) tablets (Special Order)‘ and endorsed by the pharmacy as a non-Part VIIIB special.

More For You

Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less